An AOD-9604, MOTS-c, tesamorelin stack is often discussed for fat loss, but no human trial has tested the trio. Here is what the research and FDA status show.
AOD-9604, MOTS-c, and tesamorelin are three separate peptides that some people combine into an informal fat-loss stack, but no published human trial has tested the trio together. Tesamorelin is the only one with FDA approval, and that approval covers HIV-associated lipodystrophy rather than general weight loss. AOD-9604 and MOTS-c are research chemicals with no approved human use, so the stack rests on theory and anecdote rather than clinical data.
What Each Peptide Actually Does
Each of the three compounds acts on a different part of the body's fat and energy system. That difference is the main argument people give for combining them.
| Peptide | Origin | Main mechanism | Human evidence | FDA status |
|---|---|---|---|---|
| AOD-9604 | Modified fragment of human growth hormone (HGH 176-191) | Mimics the fat-metabolizing portion of HGH; supports lipolysis and limits fat storage | A few small, older trials with modest and inconsistent fat-mass changes | Not approved for human use |
| MOTS-c | Mitochondrial-derived peptide encoded in mitochondrial DNA | Activates AMPK and influences metabolic and energy regulation | Mostly animal and cell studies; very limited human data | Not approved for human use |
| Tesamorelin | Synthetic growth hormone-releasing hormone (GHRH) analog | Stimulates pituitary growth hormone release, which reduces visceral fat | Multiple randomized controlled trials | FDA-approved (Egrifta) for HIV-associated lipodystrophy only |
Why People Stack Them Together
Comparing aod 9604 vs mots-c makes the stack logic easier to follow. AOD-9604 works directly on fat cells, MOTS-c works on mitochondria and cellular energy sensing, and tesamorelin works upstream by prompting the pituitary to release more growth hormone.
In theory, that gives three independent levers: direct fat breakdown, better metabolic efficiency, and higher endogenous growth hormone. In practice, no study has shown that pulling all three levers at once produces better results than pulling one.
It also helps to separate marketing language from biology. A combination that sounds additive on a product page can be redundant in the body, especially when two compounds influence pathways that overlap.
Does Any Human Research Support the Stack?
No clinical trial has tested AOD-9604, MOTS-c, and tesamorelin as a single protocol. There are no registered human studies that administer aod 9604 and mots-c together, with or without a GHRH analog. Even the simpler pairing of aod 9604 with tesamorelin has never been compared head-to-head in a controlled human trial.
The table below separates common claims from what the published literature actually supports.
| Common assumption | What the evidence supports |
|---|---|
| Three mechanisms multiply results | No combination data exist, and the pathways may overlap or be redundant. |
| Tesamorelin's trial results carry over to the stack | Tesamorelin's visceral fat reductions were measured in HIV-associated lipodystrophy, not in general fat loss. |
| AOD-9604 is a proven fat burner | Human trials showed small, inconsistent changes in fat mass, and several results were not statistically significant. |
| MOTS-c is a safe "exercise mimetic" in people | Human safety and dosing data are essentially absent. |
Dosing, Timing, and Handling
There is no established dose for this combination because the combination itself has never been studied. Online protocols usually describe tesamorelin as a once-daily evening injection and AOD-9604 or MOTS-c as once-daily injections, often timed around fasting windows, but those schedules come from individual user reports rather than trials.
Doses shared in forums should be treated as unverified. Individual responses vary widely, and there is no reliable way to predict how three unstudied compounds will interact in one person.
Handling is the one area where practical advice is fairly consistent. If you reconstitute aod 9604, add the diluent slowly down the inside wall of the vial, roll the vial gently between your fingers, and skip the shaking. AOD-9604 foams easily, and reports of aod-9604 gelling up into a thick or cloudy solution usually trace back to rough mixing, a cold vial, or a poorly manufactured powder.
Store reconstituted vials in the refrigerator, keep them out of light, and discard any solution that stays heavily cloudy or contains visible particles. Peptides degrade quickly when they are warm or handled roughly.
Safety, Side Effects, and Legal Status
Safety data differ sharply across these three compounds.
- Tesamorelin: studied in randomized trials; reported side effects include injection-site reactions, joint pain, swelling, and elevated IGF-1 levels. It is contraindicated during pregnancy and in people with active malignancy.
- AOD-9604: tested in a small number of short human studies; no long-term safety data exist.
- MOTS-c: almost no human safety data; prohibited for tested athletes under anti-doping rules.
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy and is not approved for general weight loss. AOD-9604 is not FDA-approved for human use in the United States, and MOTS-c is not FDA-approved either. Both are typically sold as research chemicals labeled "not for human consumption."
Because the combination has never been studied, no one can describe its side-effect profile with confidence. If you take prescription medication, are pregnant, or have a personal or family history of cancer, the risk calculation changes. Talk with a licensed healthcare professional before starting any peptide, and never stop a prescribed treatment to experiment with research chemicals.
Bottom Line
The AOD-9604, MOTS-c, tesamorelin stack is an appealing idea with a weak evidence base. Tesamorelin has genuine trial data behind it for one specific condition, AOD-9604 has thin and mixed human data, and MOTS-c has almost no human data at all.
No study has combined the three compounds, so claims about synergy are speculative. For fat loss, options with large randomized trials behind them remain the better-supported path, and a clinician can help weigh benefits against risks.
Frequently Asked Questions
Is it safe to stack AOD-9604, MOTS-c, and tesamorelin together?
No human trial has tested that combination, so its safety profile is unknown. Tesamorelin has documented side effects such as injection-site reactions, joint pain, and elevated IGF-1, while AOD-9604 and MOTS-c lack long-term human safety data. Combining unstudied compounds raises the chance of unexpected interactions, so a conversation with a healthcare professional comes first.
Is AOD-9604 FDA-approved for weight loss?
No. AOD-9604 is not FDA-approved for any human use in the United States and is sold as a research chemical. Early human trials found only small, inconsistent changes in fat mass, and several results were not statistically significant.
How much visceral fat does tesamorelin reduce?
In randomized trials of adults with HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue by roughly 15 to 20 percent over about six months of treatment. Visceral fat tends to return after the drug is stopped, and tesamorelin is not approved for general weight loss.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.